

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Morris Reichlin and Eugen Koren

Serial No: 09/768,155 Art Unit: 1644

Filed: January 23, 2001 Examiner: R. B. Schwadron

For: *METHOD FOR TREATMENT OF SLE*

Commissioner of Patents and Trademarks
Washington, D.C. 20231

[Signature]
19

**TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE
PATENTING REJECTION OVER AN ISSUED PATENT**

Sir:

Petitioner, Oklahoma Medical Research Foundation, is the owner of the entire interest in the above-identified application and U.S. Patent No. 6,342,218, issued January 29, 2002, as evidenced by the accompanying Certificates under 37 C.F.R. § 3.73(b). Petitioner hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. §§ 154-156 and 173 as shortened by any terminal disclaimer filed prior to the grant of U.S. Patent No. 6,342,218, issued on January 29, 2002. Petitioner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and U.S. Patent No. 6,342,218 are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, petitioner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full

07/17/2003 GDUCKETT 00000004 501468 statutory term as 08768158 in 35 U.S.C. §§ 154-156 and 173 of U.S. Patent No. 6,342,218 as 55.00 DA

OMRF 158 CIP CON
078617/xx/16

U.S.S.N. 09/768,155
Filed: January 23, 2001

**TERMINAL DISCLAIMER TO OBLVIAE A
PROVISIONAL DOUBLE PATENTING REJECTION
OVER AN ISSUED U.S PATENT**

shortened by any terminal disclaimer filed prior to the patent grant, in the event that U.S. Patent No. 6,342,218: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

The undersigned (whose title is supplied below) is empowered to act on behalf of Oklahoma Medical Research Foundation.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

OKLAHOMA MEDICAL RESEARCH FOUNDATION

By: m/w J. Morgan

Name: m/w J. Morgan

Title: Vice President Business
operation

Date: 5/28/03

ATL1#576747 v1

OMRF 150 CIP CON
07RA17/00116

PTO/SB/08 (08-00)

Approved for use through 12/31/2002. GOMS 0851-0001
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCEUnder the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number.**STATEMENT UNDER 37 CFR 3.73(b)**Applicant/Patent Owner: Morris Reichlin and Eugen KorenApplication No./Patent No.: 09/768,155Filed/Issue Date: January 23, 2001Entitled: Method for Treatment of SLE

Oklahoma Medical Research Foundation, a corporation of the State of Oklahoma

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

States that it is:

- the assignee of the entire right, title, and interest; or
- an assignee of less than the entire right, title and interest.
The extent (by percentage) of its ownership interest is _____%
in the patent application/patent identified above by virtue of either:

A. An assignment from the inventors of U.S. Serial No. 08/800,682 filed February 14, 1997, of which the patent application identified above is a continuation. The assignment was recorded in the United States Patent and Trademark Office at Reel 8468, Frame 0660.

OR

B. A chain of title from the inventor(s) of the patent application/patent identified above, to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.


Additional documents in the chain of title are listed on a supplemental sheet.

- I Copies of assignments or other documents in the chain of title are attached.
(NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.06)


The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

April 7, 2003

Date



Larry J. Kennedy
Typed or printed name



Larry J. Kennedy
Signature

Vice President Technology Transfer
Title

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time may vary depending upon the needs of the individual case. Any comments on 20291. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

OMRF 748 CIP CON - 078#17100116

PTO/SB/65 (08-06)

Approved for use through 10/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Morris Reichlin and Eugen Koren
 Application No./Patent No.: 08/800,682 Filed/Issue Date: February 14, 1997
 Entitled: METHOD FOR TREATMENT OF SLE
Oklahoma Medical Research Foundation, a Corporation
 (Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

- the assignee of the entire right, title, and interest; or
- an assignee of less than the entire right, title and interest.
The extent (by, percentage) of its ownership interest is _____ %

In the patent application/patent identified above by virtue of either:

A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 2468, Frame 0660, or for which a copy thereof is attached.

OR

B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

Additional documents in the chain of title are listed on a supplemental sheet.

Copies of assignments or other documents in the chain of title are attached.


(NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08)

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

May 14, 2001
Date

Larry Kennedy

Typed or printed name


Signature

Director, Technology Transfer

Title

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

MAY. 29. 2003 11:17AM

HOLLAND & KNIGHT

Law Offices

HOLLAND & KNIGHT LLP

One Atlantic Center
1201 West Peachtree Street, N.E.
Suite 2000
Atlanta, Georgia 30309-3400

404-817-8500
FAX 404-881-0470
<http://www.hklaw.com>

NO. 5058 P. 1

Atlanta
Boston
Bradenton
Chicago
Fort Lauderdale
Jacksonville
Lakeland
Los Angeles
Melbourne
Miami
New York

Northern Virginia
Orlando
Providence
San Antonio
San Francisco
Seattle
St. Petersburg
Tallahassee
Tampa
Washington, D.C.
West Palm Beach

International Offices:
Caracas*
Helsinki
Mexico City
Fló da Janeiro

São Paulo
Tel Aviv*
Tokyo

*Representative Offices

JUN 16 2003

RECEIVED
TECH CENTER 1600/2900

FACSIMILE

TO:

Group 1600 Before Final	Assistant Commissioner for Patents	703-872-9305
NAME	COMPANY/FIRM	FAX NUMBER
Washington	DC	703-306-3470
CITY	STATE	(TELEPHONE NUMBER)

FROM:

Patrea L. Pabst	404-816-8473	23
NAME	TELEPHONE	TOTAL PAGES (Including Cover Sheet)

FOR THE RECORD:

DATE: April 23, 2003	URGENCY: <input type="checkbox"/> SUPER RUSH	<input type="checkbox"/> RUSH	<input type="checkbox"/> REGULAR
FAXED BY:	FILE # 078617/00116	CLIENT NAME	OMRF 158 CIP CON

CONFIRMED: YES NO

If you did not receive all of
the pages or find that they
are illegible, please call
(404) 817-8500

NAME: _____ TIME: _____

CONFIDENTIALITY NOTICE: This facsimile, along with any documents, files, or attachments, may contain information that is confidential, privileged, or otherwise exempt from disclosure. If you are not the intended recipient or a person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, printing, distribution or use of any information contained in or attached to this facsimile is strictly prohibited. If you have received this facsimile in error, please immediately notify us by facsimile or by telephone collect at the numbers stated above, and destroy the original facsimile and its attachments without reading, printing, or saving in any manner. Your cooperation is appreciated. Thank you.

MESSAGE

Applicant: Morris Reichlin and Eugen Koren

Serial No.: 09/768,155 Art Unit: 1644

Filed: January 23, 2001 Examiner: R.B. Schwadron

For: **METHOD FOR TREATMENT OF SLE**

ATL1 #509874 v1